This week's note from the instructor reviews types of risk areas that should be continuously monitored by compliance officers, as they are frequent targets for OIG reviews.
This week’s Medicare updates include the latest edition of the Medicare Quarterly Provider Compliance Newsletter, two new proposed decision memos on coverage for blood-based biomarker tests and a molecular expression test, updated information in the COVID-19 billing FAQs, and more!
The full U.S Court of Appeals declined to reconsider two recent decisions that upheld CMS’ cuts to reimbursement for certain off-campus provider-based department (PBD) visits and drugs acquired under the 340B program, the American Hospital Association (AHA) announced October 19.
The discovery of an overpayment raises serious questions about compliance requirements. Understand your organization’s reporting obligation and appropriate methods for determining overpayments.
Q: Starting January 1, 2021, CMS will be lowering reimbursement for high throughput novel coronavirus (COVID-19) diagnostic tests from $100 to $75. I understand that if certain requirements are met labs will be eligible to bill for a $25 add on code. How can we meet the requirements for the add on code?
